Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101 - Seite 3

About France 2030

Presented on October 12, 2021, by the French President, France 2030:

• Reflects a dual ambition: to transform key sectors of our economy (energy, automotive, healthcare, aeronautics, and space) through technological and industrial innovation, and to position France not just as a player, but as a leader in the world of tomorrow. From fundamental research to the emergence of an idea, to the production of a new product or service, France 2030 supports the entire life cycle of innovation, right through to industrialization.
• Is unprecedented in its scale: €54 billion will be invested to help our companies, universities and research organizations make the transition in these strategic sectors a success. The aim is to enable them to respond competitively to the ecological and attractiveness challenges of the coming world, and to create the future champions of our sectors of excellence, thereby strengthening French sovereignty and independence in key sectors. To this end, 50% of spending will be devoted to decarbonizing the economy, and 50% will be earmarked for emerging players, bringing innovation with no adverse impact on the environment (in line with the Do No Significant Harm principle).
• Will be implemented collectively: the plan is designed and deployed in consultation with local and European economic and academic players, who have helped to determine its strategic orientations and flagship actions. Project leaders are invited to submit their applications via open, demanding, and selective procedures, in order to benefit from government support.
• Managed by the Secrétariat Général pour l'Investissement on behalf of the French Prime Minister and implemented by the Agence de la Transition Ecologique (ADEME), the Agence Nationale de la Recherche (ANR), Bpifrance and the Caisse des Dépôts et Consignations (CDC).

For more information: france2030.gouv.fr

About Oncodesign Precision Medicine (OPM)

Oncodesign Precision Medicine (OPM), founded in 2022, is a biopharmaceutical company specializing in precision medicine, dedicated to the discovery of treatments for resistant and metastatic cancers.

OPM currently has two kinase inhibitors in clinical trials: OPM-101, for the treatment of chronic immuno-inflammatory digestive diseases, which demonstrated a significant therapeutic margin and lack of toxicity in phase I trials with healthy volunteers, with a phase II trials in cancer patients with severe colitis induced by treatment with immuno checkpoint inhibitors (CUII) scheduled to start at the end of 2024. OPM-201, licensed to Servier for the treatment of Parkinson's disease, completed its phase I trial in healthy volunteers this year, with phase II scheduled to start in 2025.